Healthcare / Medical DevicesIstanbul
$30.68
+0.08 (+0.26%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $501.3M · quality 63.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.9B
P/E
133.4x
↑EV/EBITDA
16.2x
↑ROE
-0.3%
↓Gross Margin
30.5%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+21.7%
FCF CAGR
—
FCF margin
8.5%
FCF / Net income
-26.28x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.87B · net income $-9.3M · FCF $243.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.87B | $2.87B | $2.74B | $2.10B | $1.60B |
| Net Income | $-9.3M | $-9.3M | $96.1M | $37.3M | $114.3M |
| EBITDA | $207.7M | $207.7M | $307.2M | $232.0M | $285.5M |
| EPS | -0.08 | -0.08 | 0.81 | 0.31 | 0.96 |
| Gross Margin | 30.5% | 30.5% | 39.5% | 44.3% | 42.7% |
| Operating Margin | 4.0% | 4.0% | 11.7% | 18.3% | 24.7% |
| Net Margin | -0.3% | -0.3% | 3.5% | 1.8% | 7.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.06 | 0.06 |
| Current Ratio | 3.58 | 3.58 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $243.7M | $243.7M | $517.2M | $501.3M | $-44.8M |
| Returns | |||||
| ROE | -0.3% | -0.3% | 3.3% | 1.8% | 7.6% |
| Valuation | |||||
| P/E | 133.39 | 133.39 | 62.96 | 98.97 | 39.96 |
| EV/EBITDA | 16.25 | 16.25 | 18.67 | 15.34 | 15.72 |
| P/B | 1.26 | 1.26 | 2.08 | 1.72 | 3.03 |
| Growth & Yield | |||||
| Revenue Growth | 4.8% | 4.8% | 30.7% | 31.4% | — |
| EPS Growth | -109.9% | -109.9% | 161.3% | -67.7% | — |
| Dividend Yield | 1.5% | 1.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.81 → -0.08
Residual
+5.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.